Key result
Patent foramen ovale is present in 38% of patients with cryptogenic stroke versus 24% of healthy adults, though the therapeutic value of transcatheter device closure requires confirmation by RCTs.
Why the study?
What is the optimal strategy (medical therapy vs transcatheter closure) for preventing recurrent stroke in patients with patent foramen ovale?
What is the optimal strategy (medical therapy vs transcatheter closure) for preventing recurrent stroke in patients with patent foramen ovale?
This review highlights that while medical therapy reduces stroke recurrence in PFO patients, the role of transcatheter closure remains to be established by randomized trials.
Medical therapy remains appropriate for PFO stroke prevention; leaves open device closure benefit until RCTs report.
Patent foramen ovale is found in 24% of healthy adults and 38% of patients with cryptogenic stroke. This ratio and case reports indicate that patent foramen ovale and stroke are associated, probably because of paradoxical embolism. In healthy people with patent foramen ovale, embolic events are not more frequent than in controls, and therefore no primary prevention is needed. However, once ischaemic events occur, the risk of recurrence is substantial and prevention becomes an issue. Acetylsalicylic acid and warfarin reduce this risk to the same level as in patients without patent foramen ovale. Patent foramen ovale with a coinciding atrial septal aneurysm, spontaneous or large right-to-left shunt, or multiple ischaemic events potentiates the risk of recurrence. Transcatheter device closure has therefore become an intriguing addition to medical treatment, but its therapeutic value still needs to be confirmed by randomised-controlled trials.
No takes yet. Share an insight, caveat, or question.
Mattle et al. (2010) conducted a review in Patent foramen ovale and cryptogenic stroke. Transcatheter device closure vs. Medical treatment was evaluated. Patent foramen ovale is present in 38% of patients with cryptogenic stroke versus 24% of healthy adults, though the therapeutic value of transcatheter device closure requires confirmation by RCTs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: